BioTime Appoints Brian Culley As CEO - Quick Facts

(RTTNews) - Biotechnology company BioTime, Inc. (BTX) announced Tuesday that the Board of Directors has implemented a new leadership structure under which Brian Culley has been appointed as the Company's Chief Executive Officer and as a member of its Board of Directors, effective September 17, 2018. Culley succeeds Co-CEOs Adi Mohanty and Michael West.

Culley is an experienced public biopharmaceutical company CEO, having served in that capacity for seven years at Mast Therapeutics, which merged in 2017 with Savara, Inc. (SVRA).

Culley's earlier positions include leadership roles in business development and technology transfer and as an early discovery researcher for Neurocrine Biosciences (NBIX).

Meanwhile, outgoing Co-CEO Adi Mohanty will now aid in the transition and continue to serve on the Boards of Asterias and OncoCyte. Michael West will now focus on full time AgeX CEO responsibilities.